Sep 2024 - Global pharmaceutical company Amneal Pharmaceuticals, Inc., and clinical-stage biopharmaceutical company Metsera, Inc., are accelerating next-generation medicines for obesity and metabolic diseases by joining forces with a portfolio of new weight loss medicines on efficient development and large-scale supply worldwide
Does Medicare cover Zepbound for weight loss
Mental Health Side Effects: Anecdotal Reports and Emerging Studies Initial reports of mental health side effects are starting to emerge
At the moment, Retatrutide is still in clinical trials and is not yet licensed anywhere in the world
Retatrutide , a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, showed up to 24.2% body weight reduction in Phase 2 trials
Since reta appears to support better blood sugar balance in experimental models, its dual action could make it a valuable compound for researchers studying metabolic function and glucose regulation